Asymchem Payload-Linker CMC Services High-Potency R&D And GMP Manufacturing

Antibody–drug conjugates (ADCs) are advancing targeted therapies, but progress depends on solving complex challenges in payload–linker development, containment, and scale-up. This video highlights how integrated R&D and manufacturing strategies can streamline the path from early discovery to commercial production.

Key capabilities include high-potency laboratories and engineered containment systems — such as rigid isolators, dual-stage HEPA filtration, and bag-in/bag-out handling — to support safe, GMP-aligned operations with highly potent compounds. It also explores continuous processing approaches, including hydrogenation technologies designed to reduce reaction risk while improving scalability and consistency. From process development and purification through lyophilization and final packaging, the workflow demonstrates how coordinated CMC infrastructure can reduce bottlenecks and support reliable technology transfer.

Learn how these approaches help accelerate ADC programs toward global commercialization.